Phase III, multicenter, randomized, open-label, controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with high-risk HER2-positive primary breast cancer presenting with residual invasive disease
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: DAIICHI-SANKYO, INC.
- Phase: III
- Execution start: 16/04/2021
- End of execution: 30/03/2028
- IP: ISABEL BLANCAS LOPEZ-BARAJAS